Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study

Institut Pasteur19 enrolled

Overview

Patients with ALS will be included in the reference center for ALS in hospital La Pitié Salpêtrière, Paris. The study proposes to investigate the pathophysiology of ALS by setting up a fibroblast bank for studying molecular, cellular and genetic parameters of the pathology. iPS (induced pluripotent stem cells) and then differentiated cells will be generated. The pathophysiology of ALS will be studied on the 3 types of cells (fibroblasts, iPS, differentiated cells).

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Amyotrophic Lateral Sclerosis

Interventions

skin biopsyPROCEDURE

biopsy 5mm maximum on healthy skin under local anaesthesia.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients over 18 years old * ALS sporadic or familial or unknown Exclusion Criteria: * known cutaneous disease not allowing the biopsy * platelets less than 10 000/m3 * suspected or known xylocain allergy

Locations (1)

Centre référent maladies rares SLA

Paris, France

Outcomes

Primary Outcomes

Success of fibroblast culture, amplification, and freezing pellets

Time frame: 2 months

Secondary Outcomes

Induced pluripotent Stem Cells generation success

Time frame: 2 years

neurones, motoneurones, glial cells obtention from fibroblasts or iPS

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.